Expert Interview
A Second look: Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Ticker(s): CHRS, OTLKInstitution: UCSF
- Assistant Professor of Ophthalmology and Vitreoretinal Surgery at UCSF Medical Center.
- Manages 800 patients with Wet AMD.
- Collaborating extensively with Duke Bioengineering in developing novel technologies to obtain far peripheral OCT imaging of the retina in an effort to detect retinal breaks early and without the challenging and uncomfortable scleral depressed exam.
Roughly how many patients with wet AMD do you currently manage?
Added By: wilson_adminWhat % of your patients are on Cimerli? Lytenava?
Added By: wilson_adminThere are many new options coming in the clinic to compete with Eylea, including long lasting inserts, gene therapy, and other mechanisms of action. Do you think the bar is much higher now that there is so much biosimilar competition?
Added By: slingshot_insightsWhat kind of level-of-confidence would you need to start switching almost all of your patients to port delivery system therapy?
Do you have any interest in the Outlook Therapeutics product? I assume it will be priced at a little bit of a higher dollar amount.
The Outlook Therapeutics product is a little different because they use compounded Avastin. Do you have a supplier you're really comfortable with for that?
Does it matter to you that there will be a Q code in April or that there are both strengths for the AMD and the DME, the 0.5 and the 0.3?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
